Free shipping on all orders over $ 500

Anacetrapib

Cat. No. M2142

All AbMole products are for research use only, cannot be used for human consumption.

Anacetrapib Structure
Synonym:

MK-0859

Size Price Availability Quantity
10mM*1mL in DMSO USD 110  USD110 In stock
1mg USD 34  USD34 In stock
5mg USD 80  USD80 In stock
10mg USD 130  USD130 In stock
50mg USD 390  USD390 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Anacetrapib (codenamed MK-0859) is a potent cholesteryl ester transfer protein (CETP) inhibitor being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Anacetrapib binds reversibly and dalcetrapib covalently to CETP. Anacetrapib inhibited CETP-mediated cholesteryl ester and triglyceride transfer with similar potencies. Anacetrapib potently blocks CE and TG transfer in 95% human serum. Single doses of anacetrapib markedly and dose-dependently inhibited serum CETP activity with peak effects of approximately 90% inhibition at t(max) and approximately 58% inhibition at 24 h post-dose. In addition, Anacetrapib promotes reverse cholesterol transport from macrophages, and leads to a 30% increase in fecal cholesterol content.

Chemical Information
Molecular Weight 637.51
Formula C30H25F10NO3
CAS Number 875446-37-0
Solubility (25°C) DMSO 100 mg/mL
Ethanol 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Ranalletta M, et al. J Lipid Res. Biochemical characterization of cholesteryl ester transfer protein inhibitors.

[2] Krishna R, et al. Br J Clin Pharmacol. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

Related CETP Products
Obicetrapib

Obicetrapib (DEZ-001) is a selective, orally active cholesterol transporter protein (CETP) inhibitor that blocks the function of CETP and significantly reduces LDL-C while significantly increasing HDL-C levels, and may be used in studies related to atherosclerosis and Alzheimer's disease (AD).

Dalcetrapib

Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol.

Evacetrapib

Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP which inhibited human recombinant CETP protein (5.5 nM IC(50)) and CETP activity in human plasma (36 nM IC(50)) in vitro.

Torcetrapib

Torcetrapib (CP-529414) is a prototype cholesteryl ester transfer protein (CETP) inhibitor with potential for decreasing atherosclerotic disease, increased cardiovascular events in clinical trials.

  Catalog
Abmole Inhibitor Catalog




Keywords: Anacetrapib, MK-0859 supplier, CETP, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.